Skin permeability improving agent and food for improving skin permeability

Abstract

The present disclosure relates to a skin permeability improver comprising an extract extracted from a plant containing a rose anthocyanidin-based compound.

Description

[0001] Cross-reference to related applications

[0002] This international application claims priority to international application PCT / JP2023 / 035806, filed with the Japan Patent Office on September 29, 2023, pursuant to the Patent Cooperation Treaty, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This disclosure relates to a skin radiance enhancer and a food product for improving skin radiance. Background Technology

[0004] In modern times, people's interest in maintaining beautiful skin is growing daily. Skin's radiance is one of the key factors in maintaining beautiful skin, leading to a continuous increase in demand for cosmetics and other products that achieve this radiance.

[0005] To improve skin translucency, various topical formulations have been developed to date. For example, Patent Document 1 discloses a skin translucency enhancer containing extracts of Lycium barbarum leaves and / or lotus seed germ extracts as active ingredients, which improves skin translucency by inhibiting the carbonylation of stratum corneum proteins.

[0006] Existing technical documents

[0007] Patent documents

[0008] Patent Document 1: Japanese Patent Application Publication No. 2012-41276 Summary of the Invention

[0009] The technical problem that the invention aims to solve

[0010] The inventors conducted extensive research on new substances that can improve the skin's translucency.

[0011] One aspect of this disclosure aims to provide a novel skin translucency enhancer.

[0012] Technical solutions to the problem

[0013] One aspect of this disclosure is a skin radiance enhancer comprising an extract derived from plants containing rosacyanin-like compounds.

[0014] According to one of the methods disclosed herein, the skin's translucency can be improved by promoting blood circulation in the skin.

[0015] According to one of the methods disclosed herein, the skin's translucency can be improved by reducing sebum secretion.

[0016] According to one of the methods disclosed herein, dull skin can be improved by promoting blood circulation in the skin.

[0017] According to one aspect of this disclosure, the visibility of skin pores can be improved by reducing sebum secretion.

[0018] According to one embodiment of this disclosure, the skin radiance enhancer can be administered orally.

[0019] One aspect of this disclosure is a food product for improving skin radiance, which contains the aforementioned skin radiance enhancer.

[0020] The effects of the invention

[0021] Based on the above composition, a novel skin translucency enhancer can be provided. This skin translucency enhancer is used to improve skin translucency, and more preferably, it improves skin translucency by promoting blood circulation and / or reducing sebum secretion. Attached Figure Description

[0022] Figure 1 This is a chart representing the visual evaluation results of skin translucency. It shows the change (%) in skin translucency in the test product group and the control product group 4 weeks after ingestion of the test product or the control product, with the pre-test skin translucency as 100%. The change is expressed as mean ± standard error (se).

[0023] Figure 2 This is a graph representing the measurement results of sebum levels. It shows the change (%) of sebum levels in the test product intake group and the control product intake group 4 weeks after ingestion of the test product or the control product, with the pre-test sebum level as 100%. The change is expressed as mean ± standard error.

[0024] Figure 3 This is a graph representing the measurement results of the hemoglobin index. It shows the change (%) of the hemoglobin index in the test group and the control group 4 weeks after ingestion of the test product or the control product, with the pre-test hemoglobin index as 100%. The change is expressed as mean ± standard error.

[0025] Figure 4 This is a graph representing the measurement results of facial surface temperature. It shows the change (%) in surface temperature in the test product intake group and the control product intake group 4 weeks after ingestion of the test product or the control product, with the pre-test surface temperature as 100%. The change is expressed as mean ± standard error.

[0026] Figure 5 It indicates the degree of skin redness (a *A graph showing the measurement results of ) . It shows the degree of skin redness before the test (a * When the concentration is 100%, the degree of skin redness (a) in the test product intake group and the control product intake group 4 weeks after ingestion of the test product or the control product is as follows: * The change is expressed as mean ± standard error.

[0027] Figure 6 This is a chart representing the visual evaluation results of darkening. It shows the change (%) in darkening in the test product intake group and the control product intake group 4 weeks after ingestion of the test product or the control product, with the pre-test darkening as 100%. The change is expressed as mean ± standard error.

[0028] Figure 7 This is a chart representing the visual evaluation results of blackheads in pores. It shows the change (%) in blackheads in the test product group and the control group 4 weeks after ingestion of the test product or the control product, with the pre-test blackhead level as 100%. The change is expressed as mean ± standard error.

[0029] Figure 8A This is a graph showing the analysis results of the total number of pores in a replicated image of the cheek. It shows the change (%) in the total number of pores in the test product group and the control group 4 weeks after taking the test product or control product, with the total number of pores before the experiment as 100%. The change is expressed as mean ± standard error.

[0030] Figure 8B This is a graph showing the analysis results of the difference in pore brightness and darkness in a replicated image of the cheek. It shows the change (%) in pore brightness and darkness in the test product group and the control product group 4 weeks after ingestion of the test product or the control product, with the pre-experiment pore brightness and darkness difference as 100%. The change is expressed as mean ± standard error. Detailed Implementation

[0031] The skin radiance enhancer disclosed herein is an extract derived from plants containing rose anthocyanin compounds.

[0032] Rosacyanin is a type of polyphenol discovered as a pigment in plants of the Rosaceae family. Examples of rosacyanin compounds include, but are not limited to, rosacyanin A1, rosacyanin B, and rosacyanin A2.

[0033] Plants containing anthocyanin compounds include, for example, plants of the Rosaceae family, with those having purple / blue hues being preferred. Furthermore, in this disclosure, Rosaceae plants with purple / blue hues are also referred to as blue roses. Examples of Rosaceae plants with purple / blue hues include: Blue Sky, Ondina, Secret Parfum, Purple Fragrance, Charles de Gaulle, Silver Star, Sterling Silver, Azure Dragon, Turn Blue, Novalis, Purple Time, Blue Bayou, Blue Moon, Blue Light, Blue River, Lovely Blue, Le Ciel Bleu, Blue Track, Something Blue, Misty Purple, Rhapsody in Blue, Bleu Chateau, Purple Garden, Violet Hill, Blue Sky, Three Feathers, WaltzTime, Wisteria, Blue Heaven, Cool, Lapis Lazuli, Kinda Blue, Blue Gravity. Gravity, Blue Angel, Purple Cloud, Melody Parfum, Angel Face, Prelude, Lady X, Grey Pearl, Lavender Pinocchio, Lilac Charm, Simone, WaltzTime, Glacier, Twilight, Ivory Tower, Kölner Karneval, Overture, Blue Monday, Cardinal de Richelieu, Stainless Steel, Grand Blue, News, Blue Ribbon, Blue Nile, Twilight, Madame Violet, Watarasawa, etc.As for plants containing anthocyanin compounds, one of the above-mentioned plants can be used, or two, three, or more can be used in combination. Furthermore, the extraction raw materials are not limited to the above-mentioned plants; all plants containing anthocyanin compounds can be used as extraction raw materials.

[0034] Extracts derived from plants containing anthocyanins are extracts obtained from plants containing anthocyanins using any method. As a specific example, the plant part used for extraction can be petals or other parts. Furthermore, extracts derived from plants containing anthocyanins may not necessarily contain anthocyanins themselves, as long as the extract shows an effect of improving skin radiance. Additionally, extracts derived from plants containing anthocyanins may not contain rosadelphin-like compounds.

[0035] Extracts from plants containing anthocyanin compounds can be obtained using conventional methods for extracting plants.

[0036] Examples of extraction solvents include: water (including hot water), alcohols (such as methanol, anhydrous ethanol, ethanol and other lower alcohols, or polyols such as propylene glycol, 1,3-butanediol, glycerol, dipropylene glycol, etc.), ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile, ethyl acetate, organic solvents such as xylene, benzene, chloroform, animal oils, vegetable oils, supercritical carbon dioxide, and combinations of two or more of the above.

[0037] The extraction time can be, for example, from 0.1 to 96 hours, but is not limited to this. Furthermore, the extraction temperature can be, for example, from 1 to 120°C, but is not limited to this.

[0038] In addition, the extract disclosed herein includes, besides the extract obtained using plants as the extraction raw material, a diluted or concentrated extract, a dried extract, or any one of the aforementioned crude or refined products. When drying the obtained extract, known drying methods (e.g., freeze-drying, vacuum drying, and hot air drying) can be used. Furthermore, when purifying the obtained extract, known purification methods (e.g., ion exchange resin treatment and activated carbon treatment) can be used.

[0039] The skin translucency enhancer disclosed herein is used to improve the translucency of the skin. Furthermore, the Japan Cosmetic Industry Association defines "skin translucency" as a state where the skin is free of dullness and appears translucent.

[0040] In addition to visual inspection by experts, indicators such as light transmittance, image analysis, saturation, and hue angle can be used to evaluate the skin's translucency.

[0041] Furthermore, in this disclosure, skin translucency can be improved by promoting blood circulation. Specifically, by promoting blood circulation, the amount of oxyhemoglobin in the blood increases, resulting in reduced absorption of red areas and increased red reflectance. Since there is a correlation between blood flow and the visual perception of dullness, dullness can be improved by promoting blood circulation. Moreover, by improving dullness, the translucency of the skin can be improved, thereby enhancing the skin's overall radiance.

[0042] In addition, improved blood circulation can be indicated by L, which represents the brightness of skin tone. * Value, indicating the degree of skin redness (a) * The values, hemoglobin index (indicating the hemoglobin content in the skin), and HbSO2 index (indicating the proportion of oxyhemoglobin) are used as indicators for evaluation.

[0043] Therefore, another aspect of this disclosure can be a blood circulation enhancer comprising an extract from plants containing rose anthocyanin compounds. In addition to improving skin radiance, the blood circulation enhancer of this disclosure can also be used for various purposes related to promoting blood circulation.

[0044] Furthermore, another aspect of this disclosure could be a body temperature-raising agent comprising an extract from plants containing rose anthocyanin-like compounds. Increased body temperature promotes blood circulation in the skin. Therefore, the same effect as described above, which enhances skin radiance by promoting blood circulation, can be expected.

[0045] In addition to improving skin permeability, the body temperature raising agent disclosed herein can also be used for various purposes related to body temperature raising.

[0046] Furthermore, in this disclosure, skin clarity can be improved by reducing sebum secretion. Specifically, by reducing sebum secretion, the condition where excessive sebum causes pores to enlarge and become more noticeable can be prevented. Additionally, the accumulation of dirt in pores due to excessive sebum, leading to the formation of keratin plugs, can be prevented, and the formation of blackheads due to sebum oxidation caused by ultraviolet rays can be inhibited. This improves the visibility of skin pores. Furthermore, by improving the visibility of skin pores, the skin's radiance can be improved, thereby enhancing skin clarity.

[0047] In addition, sebum production and blackheads in pores can be used as indicators to evaluate the reduction in sebum secretion. Furthermore, the average area, total number, standard deviation of angle, roundness, and light-dark difference of pores can be used as indicators to evaluate the visibility of skin pores.

[0048] Therefore, another aspect of this disclosure can be a sebum secretion inhibitor comprising an extract from plants containing rose anthocyanin compounds. In addition to improving skin radiance, the sebum secretion inhibitor of this disclosure can also be used for various purposes related to reducing sebum secretion.

[0049] The skin radiance enhancer disclosed herein may be included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals.

[0050] The food form containing the skin translucency enhancer disclosed herein can be any form and is not limited. Specific food forms may include, for example: ordinary food, ordinary beverage, supplement, health food, functional food, food for specific health purposes and other health functional foods and foods for specific purposes, soft drinks, tea drinks, health drinks, alcoholic beverages such as wine, pastries, rice dishes, bread dishes, noodles dishes, cooked food, seasonings, etc.

[0051] Furthermore, there are no restrictions on the dosage forms of cosmetics, pharmaceuticals, and quasi-pharmaceuticals containing the skin translucency enhancer disclosed herein. Specific dosage forms for cosmetics, pharmaceuticals, and quasi-pharmaceuticals include, for example, capsules, tablets, powders, granules, liquids, emulsions, creams, gels, ointments, tablets, mousses, etc.

[0052] The content of extracts from plants containing rose anthocyanin compounds in the skin translucency enhancer is 0.01 to 100% by weight, preferably 1 to 90% by weight, more preferably 5 to 80% by weight, and even more preferably 10 to 50% by weight, relative to 100% by weight of the skin translucency enhancer.

[0053] Furthermore, the content of extracts from plants containing anthocyanin compounds in the skin translucency enhancer is preferably 15-25% by weight, for example, 20% by weight, relative to 100% by weight of the skin translucency enhancer. By keeping the content of extracts from plants containing anthocyanin compounds in the skin translucency enhancer within this range, both the stickiness of the skin translucency enhancer and the skin translucency can be effectively improved.

[0054] Furthermore, when the skin translucency enhancer disclosed herein is included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals, it may also be included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals in a manner containing the aforementioned amount, as an extract derived from plants containing rose anthocyanin compounds.

[0055] Furthermore, skin-brightening agents can contain any ingredients other than extracts from plants containing anthocyanin compounds. Examples of such ingredients include: base materials, solvents, preservatives, oils, excipients, binders, disintegrants, preservatives, coating agents, dispersants, fluidizing agents, stabilizers, flavoring agents, colorants, pH adjusters, surfactants, and fragrances.

[0056] The skin permeability enhancement agent disclosed herein can be administered to the subject in various forms of administration, preferably orally.

[0057] The dosage of the skin permeability enhancer disclosed herein is determined by considering factors such as the subject's age, sex, weight, method of use, and dosage. When administered orally, the daily dose of the extract from plants containing rose anthocyanin compounds in the skin permeability enhancer is preferably 0.1 mg / day to 500 mg / day, more preferably 1 mg / day to 250 mg / day, and even more preferably 10 mg / day to 200 mg / day. By keeping the dosage of the skin permeability enhancer within this range, skin permeability can be effectively improved.

[0058] Furthermore, the skin radiance enhancer disclosed herein can be administered as a single dose or repeatedly over a long or short period. There is no limit to the frequency of administration; it can be administered three times a day, twice a day, once a day, once every two days, once every three days, once a week, once every two weeks, once a month, etc. Furthermore, there is no limit to the duration of administration; it can be administered for one day, two days, three days, one week, two weeks, four weeks, six months, one year, or longer.

[0059] Another aspect of this disclosure is a method for improving skin translucency, which includes administering to a subject a skin translucency enhancer comprising an extract derived from a plant containing anthocyanin compounds. Furthermore, another aspect of this disclosure relates to the use of extracts derived from plants containing anthocyanin compounds in the preparation of skin translucency enhancers.

[0060] [Example]

[0061] Example 1: Preparation of the formulation

[0062] Two types of blue roses bred by Kinji Co., Ltd. of Japan were used as the plant containing anthocyanin compounds. Five times the amount of water was added to a mixture of equal amounts of these blue rose petals (total petal weight: 4 kg), and the mixture was heated at 90–100°C for 2 hours, followed by pressing to obtain an extract. Dextrin (Max1000 (manufactured by Matsutani Chemical Industry Co., Ltd. of Japan)) was added to this extract at a solids ratio of 1:4, and the mixture was freeze-dried to obtain an extract powder. Capsules containing this extract powder were prepared as test samples. The content of the extract (i.e., the extract) from the plant containing anthocyanin compounds was 20% by weight relative to 100% by weight of the capsule. Additionally, capsules containing only dextrin were prepared as a control.

[0063] Example 2: Various Tests

[0064] Using the test samples and control samples prepared in Example 1, various experiments (hereinafter referred to as "experiments") related to skin improvement in the subjects were conducted. Furthermore, the experimental plan and implementation followed the spirit of the Declaration of Helsinki (revised at the 2013 Fortaleza Conference), and were reviewed by the ethics review committee to ensure compliance with ethical and social considerations, and approved after confirming its reasonableness. Subjects were informed of the origin, purpose, methods, handling of personal information in the experimental results, subjects' rights, and methods for counseling and compensation in the event of adverse events. Participants were confirmed in writing as voluntarily participating in the experiment before its implementation. Additionally, any substantial deviation from the experimental plan required approval from the ethics review committee.

[0065] (1) Selection of subjects

[0066] Forty-eight individuals who met the following selection criteria and did not violate the following exclusion criteria were selected as subjects for this experiment through self-nomination.

[0067] Selection Criteria

[0068] • Healthy Japanese women aged 40 to 50 at the time of obtaining consent

[0069] • People with skin type III or IV (according to Fitzpatrick's classification)

[0070] People who are aware of their dry skin

[0071] Exclusion criteria

[0072] People suffering from skin diseases such as psoriasis

[0073] People suffering from skin diseases such as atopic dermatitis

[0074] • People who take or apply medications that may affect test results

[0075] People with contact allergies or who may experience allergic symptoms

[0076] People who regularly visit dermatology clinics

[0077] • People with eczema, rashes, sunburn, pigmentation, scratch marks, etc. on the test sites

[0078] • People who are pregnant, may become pregnant, or are breastfeeding

[0079] • Individuals who are participating in other trials that interfere with this trial at the start of the trial, or individuals who plan to participate in other trials that interfere with this trial during the scheduled period of the trial.

[0080] • People with tattoos, body paint, or other body art on their test sites

[0081] • Individuals who have received chemical peels, laser treatments, phototherapy, skin injections, surgical treatments, or cosmetic treatments on the test site within 4 weeks prior to the start of the trial.

[0082] • Those deemed unsuitable to participate in the experiment by the person in charge of the experiment.

[0083] (2) Intake

[0084] Participants were randomly assigned to either the test product group or the control product group using a stratified randomization method. Participants ingested a prescribed dose (1 capsule) of either the test product or the control product before bedtime. The intake period was set at 4 weeks, with participants taking either the test product or the control product for 4 consecutive weeks.

[0085] (3) Evaluation or measurement

[0086] To facilitate intergroup comparisons between the test product group and the control product group, a double-blind trial was conducted. Evaluations or measurements were performed twice: before the start of the trial and twice after four weeks of continuous use of either the test product or the control product. Before the start of the trial and after four weeks of continuous use of either the test product or the control product, subjects cleansed their faces with makeup remover and facial cleanser, and then sat quietly for approximately 20 minutes in a room maintained at a temperature of 21.0 ± 0.3°C and a relative humidity of 45.0 ± 2.0%. After the skin had acclimatized to the test environment, the following evaluation items were assessed or measured.

[0087] • Evaluation of transparency based on visual perception

[0088] ·Amount of sebum

[0089] Hemoglobin index measured using a colorimeter

[0090] Body surface temperature

[0091] • The degree of skin redness measured using a colorimeter (a * )

[0092] • Evaluation of dullness based on visual perception

[0093] • Evaluation of blackheads in pores based on visual perception

[0094] • Pore analysis using copied images

[0095] (4) Changes / Missing Measurement Status

[0096] If a participant may withdraw from the trial due to health conditions or personal reasons, their health and wishes will be given priority in accordance with the spirit of the Declaration of Helsinki. Furthermore, if certain data cannot be collected for the reasons mentioned above or otherwise, that data will be treated as missing data.

[0097] Furthermore, if any of the following conditions are met, the subject will be included in the case discussion and, without specific justification, excluded from the trial analysis (report) process:

[0098] • Situations where the observation period is delayed by more than one week

[0099] • Situations where subjects were found to have seriously violated the instructions in the subject management guidelines during the trial period

[0100] • Situations where data reliability is significantly compromised due to issues such as problems during inspection.

[0101] • When the number of days of intake (when the recommended daily intake is not met) exceeds 15% of the planned number of days.

[0102] • Situations found that do not meet the selection criteria or meet the exclusion criteria

[0103] • There are other circumstances deemed appropriate as clear reasons for detachment treatment.

[0104] (5) Statistical analysis

[0105] This trial began with 48 participants, and ultimately 44 participants who did not drop out midway and did not meet the exclusion criteria were selected as the analysis subjects. For reference, unpaired t-tests were used to perform statistical analysis on the test product intake group and control product intake group at each measurement period, and Wilcoxon rank-sum tests were used to perform statistical analysis on the test product intake group and control product intake group at each measurement period.

[0106] (6) Results

[0107] (A) Evaluation of skin translucency based on visual perception

[0108] After the skin adapted to the test environment, skilled evaluators visually assessed the translucency of the subjects' facial skin, using a five-level rating system (1: completely imperceptible, 2: almost imperceptible, 3: average, 4: slightly imperceptible, 5: very noticeable). The results are as follows: Figure 1 As shown. Additionally... Figure 1 The higher the median value, the more translucent the skin appears.

[0109] Using the pre-experiment visual perception of skin translucency as 100%, the relative values ​​of skin translucency after 4 weeks of continuous use were compared. The results showed that the experimental product intake group had a trend-like difference and a higher value compared to the control product intake group. Therefore, it can be concluded that the intake of the experimental product can improve skin translucency.

[0110] (B) Sebum content

[0111] After the skin had adapted to the test environment, sebum levels were measured using a Sebumeter SM815 (Courage+Khazaka, Germany). The results are as follows: Figure 2 As shown. Additionally, in Figure 2 A higher median value indicates a greater amount of sebum.

[0112] Using pre-experiment sebum levels as 100%, the relative sebum levels after 4 weeks of continuous use were compared. The results showed a significant difference in sebum levels between the experimental group and the control group, with the experimental product showing a lower value. Therefore, it can be concluded that the intake of the experimental product can reduce sebum levels.

[0113] (C) Hemoglobin index measured using a colorimeter

[0114] After the skin had adapted to the test environment, the hemoglobin index was measured using a CM-700d colorimeter (Konica Minolta, Japan). The results are as follows: Figure 3 As shown. Additionally, in Figure 3 A higher hemoglobin index indicates more erythema on the skin or more blood flow (good blood circulation).

[0115] Using the pre-experiment hemoglobin index as 100%, the relative values ​​of hemoglobin index after 4 weeks of continuous administration were compared. The results showed that the experimental group had a significant difference and a higher value compared to the control group. Therefore, it can be concluded that the intake of the experimental product can promote blood circulation.

[0116] (D) Body surface temperature

[0117] After the skin had adapted to the test environment, facial surface temperature was measured using a non-contact infrared thermometer (CISE, Muranaka Medical, Japan). The results are as follows: Figure 4 As shown. Additionally, in Figure 4 A higher median value indicates a higher body surface temperature.

[0118] Using pre-experiment body surface temperature as 100%, the relative body surface temperature values ​​after 4 weeks of continuous administration were compared. The results showed a significant difference and a higher value in the experimental group compared to the control group. Therefore, it can be concluded that the intake of the experimental product can promote an increase in body surface temperature.

[0119] (E) Degree of skin redness as measured using a colorimeter (a * )

[0120] After the skin has adapted to the test environment, the degree of skin redness (a) is measured using a colorimeter CM-700d (Konica Minolta, Japan). * The result is as follows: Figure 5 As shown. Additionally, in Figure 5 The text indicates the degree of redness in the skin (a). * The smaller the value, the less redness the skin tone has.

[0121] The degree of skin redness before the test (a * The percentage was 100%, and the degree of skin redness was compared after 4 weeks of continuous use (a) * The relative values ​​showed that the test product intake group had a significant difference compared to the control product intake group, and the values ​​were higher. Therefore, it can be concluded that the intake of the test product can promote blood circulation.

[0122] (F) Evaluation of dullness based on visual perception

[0123] After the skin adapted to the experimental environment, skilled evaluators visually assessed the subjects' facial skin dullness, using a three-level rating system (1: no dullness, 2: difficult to judge, 3: appears dull). The results are as follows: Figure 6 As shown. Additionally, in Figure 6 The lower the median value, the less dull the skin.

[0124] Using visually perceived skin dullness as 100%, the relative values ​​of skin dullness after 4 weeks of continuous use were compared. The results showed that the experimental product group tended to have lower values ​​compared to the control group. Therefore, it can be concluded that the intake of the experimental product may improve skin dullness.

[0125] (G) Evaluation of blackheads in pores based on visual perception

[0126] After the skin adapted to the experimental environment, skilled evaluators visually assessed the blackheads and pores on the subjects' facial skin, using a three-level rating system (1: not obvious, 2: difficult to judge, 3: obvious). The results are as follows: Figure 7 As shown. Additionally, in Figure 7 The smaller the median value, the less noticeable the blackheads in the pores.

[0127] Using visually perceived blackheads as 100%, the relative values ​​of blackheads after 4 weeks of continuous use were compared. The results showed that the experimental product group tended to have lower values ​​compared to the control group. Therefore, it can be concluded that the intake of the experimental product may improve blackheads.

[0128] (H) Pore analysis using replicated images

[0129] After the skin had adapted to the test environment, a replica image of the cheek was acquired using SKIN CAST (RaptorSurvey Institute, Japan), a hydrophilic vinyl silicone impression agent. The acquired replica images were then photographed using i-Scope. An image analysis application was used to analyze the total number of pores and the difference in brightness and darkness in the photographed replica images. In the experiment, an area of ​​0.06 mm² was used. 2 The above definition of pores is as follows. The total number of pores and their brightness / darkness difference within the image analysis area (9.5 mm × 7.1 mm) were analyzed. The results are as follows... Figure 8A and Figure 8B As shown. Additionally, in Figure 8A and Figure 8B The lower the total number of pores value, the fewer the pores. Additionally, the lower the pore brightness difference value, the less noticeable the pores.

[0130] Using the number of parts identified as pores in the pre-experimental image as 100%, the relative total number of pores after 4 weeks of continuous use was compared. The results showed that the experimental group had a significant difference and a lower value compared to the control group.

[0131] Furthermore, using the difference in pore brightness in the pre-experiment replica images as 100%, the relative total number of pores was compared after 4 weeks of continuous use. The results showed a significant difference and a lower value in the experimental product intake group compared to the control product intake group. Therefore, it can be concluded that the intake of the experimental product helps to make pores less noticeable.

[0132] Example 3: Extract Analysis

[0133] The composition of the extract powder obtained in Example 1 from plants containing rose anthocyanin compounds was analyzed.

[0134] (1) Measurement conditions

[0135] <Dilution ratio>

[0136] The extract powder obtained from plants containing rose anthocyanin compounds was diluted to 20 mg / ml with ultrapure water (milliQ water) and measured. Ultrapure water (milliQ water) was used as the blank.

[0137] <LC-MS conditions>

[0138] · Liquid chromatograph

[0139] Separation column: ACQUITY UPLC BEH C18, 1.7 μm, 2.1 mm × 75 mm

[0140] Mobile phase A: 0.1% formic acid - ultrapure water

[0141] Mobile phase B: 0.1% formic acid - acetonitrile

[0142] Gradient: 5% B (0 min) to 98% B (10 min - 15 min)

[0143] Flow rate: 0.5 mL / min

[0144] Injection volume: 1 μL

[0145] Thermostat: 40 °C

[0146] · Mass spectrometer

[0147] Ion source: ESI - positive, ESI - negative

[0148] Nebulizer: 2.5 bar

[0149] Dry gas: 8.0 L / min

[0150] Dry temperature: 200 °C

[0151] Mass range: m / z 100 - 3000

[0152] (2)Results

[0153] The results are shown in Table 1 below.

[0154] [Table 1]

[0155]

[0156] Mass analysis of extract powders from plants containing rose anthocyanin compounds revealed numerous peaks. Furthermore, compounds predicted based on their mass were estimated (see “Prediction” in Table 1). Multiple divalent (2-) ions were observed in the negative mode measurements. In both positive and negative modes, ions exhibiting very similar m / z values ​​were sometimes observed across multiple time intervals, indicating the presence of structural isomers.

[0157] Furthermore, the mass (m / z, mass-to-charge ratio) of the rose anthocyanin compounds (specifically rose anthocyanin A1, rose anthocyanin B, and rose anthocyanin A2) and the delphinidin compounds (specifically delphinidin A1, delphinidin B, and delphinidin A2) is shown in Table 2 below. Additionally, the mass (m / z, mass-to-charge ratio) of the rose anthocyanin compounds is referenced in Yuko Fukui et al. Tetrahedron Letters 43, 2637-2639, (2002) and Yuko Fukui et al. ScienceDirect Tetrahedron 62, 9661-9670, (2006). Furthermore, the mass-to-charge ratio (m / z) of the delphinidin compounds is referenced in International Publication No. 2015 / 178358.

[0158] [Table 2]

[0159]

[0160] The results of the quality analysis showed that no components with the same mass (m / z) as the rose anthocyanins and delphinidin compounds were detected in the extract powder extracted from plants containing rose anthocyanins. In other words, this indicates that the extract powder extracted from plants containing rose anthocyanins does not contain rose anthocyanins and delphinidin compounds. Furthermore, the experimental results in Example 2 above suggest that the effect should be attributed to one or more components in the extract powder extracted from plants containing rose anthocyanins that are different from the rose anthocyanins and delphinidin compounds.

Claims

1. A skin translucency enhancement agent, characterized in that, It contains extracts derived from plants containing anthocyanin compounds.

2. The skin translucency enhancement agent according to claim 1, characterized in that, Improve skin's radiance by promoting blood circulation.

3. The skin translucency enhancement agent according to claim 1, characterized in that, Improve skin's radiance by reducing sebum secretion.

4. The skin translucency enhancement agent according to claim 2, characterized in that, Improve dull skin by promoting blood circulation.

5. The skin translucency enhancement agent according to claim 3, characterized in that, Improve the visibility of skin pores by reducing sebum secretion.

6. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The skin radiance enhancer is administered orally.

7. A food product for improving skin radiance, characterized in that, The product comprises the skin translucency enhancer as described in any one of claims 1 to 5.

8. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The extract does not contain rose anthocyanin compounds.

9. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The extract does not contain delphinidin compounds.

Images